MAPP BIOPHARMACEUTICAL, INC.
...UEIM9V9QTHR1H28·Profile updated 2026-05-13
Awards tracked
3
Total amount
$352.4M
Date range
2026-02-20 → 2026-05-12
Primary sector
Volume
$/month, last 24
About this recipient
MAPP BIOPHARMACEUTICAL, INC. has received $352.4M in tracked federal funding across the ingest window.
The largest single source of funding is Department of Health and Human Services, which dominates the recipient's federal portfolio. We surface the full breakdown of contracts and grants below.
A longer, LLM-generated profile becomes available for the top entities by total $ awarded. We do not take editorial direction from recipients.
Portfolio by sector
Sectors classified by LLM on each award.
- biotech6 awards$704.7M 100%
Portfolio status
Based on each award's period of performance.
Active
2
active67% of awards
Expiring (≤90d)
0
expiring · 30d0% of awards
Expired
1
expired33% of awards
No POP
0
—0% of awards
Top awarding agencies
Department of Health and Human Services
$352.4M 100%
Based on 3 awards totaling $352,368,726.
Awards
Top 3 by amount
| Action date | Recipient | Agency | Amount | Description | Sector | Status |
|---|---|---|---|---|---|---|
| 2026-05-12 | MAPP BIOPHARMACEUTICAL, INC. | Department of Health and Human Services | $184,786,391 | PROCUREMENT OF THERAPEUTICS FOR EBOLA, SUDAN AND MARBURG VIRUSES | — | active |
| 2026-02-20 | MAPP BIOPHARMACEUTICAL, INC. | Department of Health and Human Services | $110,877,385 | THIS COST-PLUS-FIXED-FEE CONTRACT WITH MAPP BIOPHARMACEUTICAL, INC. (MAPP OR CONTRACTOR) IS FOR THE DEVELOPMENT OF MAPP?S THERAPEUTIC INTERVENTION MBP091, AS AN IMMUNOTHERAPY FOR THE TREATMENT OF MARBURG VIRUS INFECTION. | — | active |
| 2026-05-08 | MAPP BIOPHARMACEUTICAL, INC. | Department of Health and Human Services | $56,704,950 | IGF::OT::IGF | — | expired |
Sources
USAspending.gov — all awards for this UEI →SAM.gov entity registration →
Profile compiled from publicly available USAspending.gov records, ingested and entity-resolved by The Buildout's pipeline.